Gralise (Gabapentin) Patent Expiration, LOE Window & CMS Spending

Gralise (Gabapentin) by Almatica: Off-Patent Genericized (AB Competition), 20 AB generics, $15.4M 2024 CMS Part D & Medicaid spend, and $958 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlmatica
FDA Application & PathwayN022544 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors20
2024 CMS Total Public Spend$15.4M
2024 Medicare Part D Spend$12.5M
2024 Medicaid Spend$2.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($958 intro WAC)